Nothing Special   »   [go: up one dir, main page]

BRPI0920276A2 - várias composições para exclusão de exon dmd - Google Patents

várias composições para exclusão de exon dmd

Info

Publication number
BRPI0920276A2
BRPI0920276A2 BRPI0920276A BRPI0920276A BRPI0920276A2 BR PI0920276 A2 BRPI0920276 A2 BR PI0920276A2 BR PI0920276 A BRPI0920276 A BR PI0920276A BR PI0920276 A BRPI0920276 A BR PI0920276A BR PI0920276 A2 BRPI0920276 A2 BR PI0920276A2
Authority
BR
Brazil
Prior art keywords
exclusion
various compositions
dmd
exon
exon dmd
Prior art date
Application number
BRPI0920276A
Other languages
English (en)
Inventor
Peter Sazani
Ryszard Kole
Original Assignee
Avi Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920276(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avi Biopharma Inc filed Critical Avi Biopharma Inc
Priority to BR122020021379-5A priority Critical patent/BR122020021379B1/pt
Priority to BR122020021368-0A priority patent/BR122020021368B1/pt
Publication of BRPI0920276A2 publication Critical patent/BRPI0920276A2/pt
Publication of BRPI0920276B1 publication Critical patent/BRPI0920276B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/107—Temperature of melting, i.e. Tm

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0920276-5A 2008-10-24 2009-10-23 oligonucleotídeo antissenso, composição que compreende o mesmo e uso do dito oligonucleotídeo para tratar distrofia muscular BRPI0920276B1 (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
BR122020021379-5A BR122020021379B1 (pt) 2008-10-24 2009-10-23 oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
BR122020021368-0A BR122020021368B1 (pt) 2008-10-24 2009-10-23 composto que compreende um composto antisenso, composição que compreende o mesmo e uso do referido composto para preparação de medicamento para indução de salto do éxon 53

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10841608P 2008-10-24 2008-10-24
US61/108.416 2008-10-24
PCT/US2009/061960 WO2010048586A1 (en) 2008-10-24 2009-10-23 Multiple exon skipping compositions for dmd

Publications (2)

Publication Number Publication Date
BRPI0920276A2 true BRPI0920276A2 (pt) 2016-09-06
BRPI0920276B1 BRPI0920276B1 (pt) 2021-06-08

Family

ID=41510869

Family Applications (3)

Application Number Title Priority Date Filing Date
BR122020021379-5A BR122020021379B1 (pt) 2008-10-24 2009-10-23 oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
BR122020021368-0A BR122020021368B1 (pt) 2008-10-24 2009-10-23 composto que compreende um composto antisenso, composição que compreende o mesmo e uso do referido composto para preparação de medicamento para indução de salto do éxon 53
BRPI0920276-5A BRPI0920276B1 (pt) 2008-10-24 2009-10-23 oligonucleotídeo antissenso, composição que compreende o mesmo e uso do dito oligonucleotídeo para tratar distrofia muscular

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR122020021379-5A BR122020021379B1 (pt) 2008-10-24 2009-10-23 oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
BR122020021368-0A BR122020021368B1 (pt) 2008-10-24 2009-10-23 composto que compreende um composto antisenso, composição que compreende o mesmo e uso do referido composto para preparação de medicamento para indução de salto do éxon 53

Country Status (22)

Country Link
US (14) US8871918B2 (pt)
EP (7) EP2762567B1 (pt)
JP (10) JP5864257B2 (pt)
KR (5) KR20110082576A (pt)
CN (3) CN102203253B (pt)
AU (1) AU2009308167B2 (pt)
BR (3) BR122020021379B1 (pt)
CA (2) CA2740328A1 (pt)
CY (1) CY1122369T1 (pt)
DK (1) DK3133160T3 (pt)
ES (2) ES2714787T3 (pt)
HK (1) HK1200868A1 (pt)
HR (1) HRP20190387T1 (pt)
HU (1) HUE042979T2 (pt)
IL (6) IL313162A (pt)
LT (1) LT3133160T (pt)
PL (1) PL3133160T3 (pt)
PT (1) PT3133160T (pt)
SI (1) SI3133160T1 (pt)
TR (1) TR201902952T4 (pt)
TW (6) TWI639700B (pt)
WO (1) WO2010048586A1 (pt)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004083432A1 (en) * 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
DE602004028930D1 (de) 2003-04-29 2010-10-14 Avi Biopharma Inc Zusammensetzungen zur verbesserung der antisense-wirksamkeit und des transports von nukleinsäureanalog in zellen
AU2005208710A1 (en) 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP2500430B1 (en) 2004-06-28 2017-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
ES2694726T3 (es) * 2007-06-29 2018-12-26 Sarepta Therapeutics, Inc. Conjugados peptídicos específicos de tejido y métodos
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009054725A2 (en) * 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
AU2008345033B2 (en) * 2007-12-28 2014-04-03 Sarepta Therapeutics, Inc. Immunomodulatory agents and methods of use
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN102203253B (zh) 2008-10-24 2016-04-06 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
ES2562658T3 (es) * 2008-10-27 2016-03-07 Biomarin Technologies B.V. Procedimientos y medios para el salto eficiente del exón 45 en el pre-ARNm de la distrofia muscular de Duchenne
ES2593836T3 (es) 2009-04-24 2016-12-13 Biomarin Technologies B.V. Oligonucleótido que comprende una inosina para tratar la DMD
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011057350A1 (en) 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies
BR112012031363A2 (pt) 2010-05-28 2021-10-26 Sarepta Therapeutcs, Inc Análogos de oligonucleotídeo tendo ligações intersubunidades modificadas e/ou grupos terminais.
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US10017763B2 (en) 2010-09-03 2018-07-10 Sarepta Therapeutics, Inc. dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
JP2014507143A (ja) * 2011-02-08 2014-03-27 ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング／ビジネス／アズ キャロライナズ ヘルスケア システム アンチセンスオリゴヌクレオチド
WO2012150960A1 (en) * 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US20140080896A1 (en) * 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR102271212B1 (ko) * 2011-11-18 2021-07-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
EP2788488B1 (en) 2011-12-08 2018-03-21 Sarepta Therapeutics, Inc. Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
IN2014DN06220A (pt) * 2011-12-28 2015-10-23 Nippon Shinyaku Co Ltd
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
JP6928025B2 (ja) * 2012-01-27 2021-09-01 バイオマリン テクノロジーズ ベー．フェー． デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するｒｎａ調節オリゴヌクレオチド
AU2013216832B2 (en) 2012-02-09 2016-09-22 Novus International Inc. Heteroatom containing cyclic dimers
US9920085B2 (en) 2012-03-20 2018-03-20 Sarepta Therapeutics, Inc. Boronic acid conjugates of oligonucleotide analogues
DE102012103041A1 (de) 2012-04-10 2013-10-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung der dilativen Kardiomyopathie mittels Antisense-Oligonucleotiden
WO2013163628A2 (en) 2012-04-27 2013-10-31 Duke University Genetic correction of mutated genes
RU2674600C2 (ru) * 2012-07-03 2018-12-11 Просенса Текнолоджиз Б.В. Олигонуклеотид для лечения пациентов с мышечной дистрофией
BR112015000494A2 (pt) 2012-07-12 2017-06-27 Novus Int Inc matriz e composições da camada para a proteção dos biotivos
KR20200143739A (ko) * 2012-12-20 2020-12-24 사렙타 쎄러퓨틱스 인코퍼레이티드 근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물
US20160040162A1 (en) * 2013-03-14 2016-02-11 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
IL293975A (en) * 2013-03-14 2022-08-01 Sarepta Therapeutics Inc Preparations that skip axon for the treatment of muscular dystrophy
NZ732507A (en) 2013-03-15 2018-08-31 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
US10517869B2 (en) 2013-12-24 2019-12-31 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
AU2015227733B2 (en) 2014-03-12 2019-10-31 National Center Of Neurology And Psychiatry Antisense nucleic acids
AR101542A1 (es) 2014-05-23 2016-12-28 Genzyme Corp Porciones de múltiples oligonucleótidos de péptidos transportadores
RS59764B1 (sr) * 2014-06-17 2020-02-28 Nippon Shinyaku Co Ltd Antismisaona nukleinska kiselina za upotrebu u lečenju dišenove mišićne distrofije
CN106714845A (zh) * 2014-08-11 2017-05-24 得克萨斯州大学系统董事会 通过crispr/cas9介导的基因编辑预防肌营养不良
US20160074532A1 (en) 2014-09-07 2016-03-17 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
EP3085785A1 (en) * 2015-04-22 2016-10-26 Université de Strasbourg Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy
BR112017024929A2 (pt) * 2015-05-19 2018-07-31 Sarepta Therapeutics, Inc. conjugados de oligonucleotídeo-peptídeo
EP3302489A4 (en) 2015-06-04 2019-02-06 Sarepta Therapeutics, Inc. METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES
EP3307891B8 (en) * 2015-06-10 2019-11-13 Association Institut de Myologie Combined therapy for duchenne muscular dystrophy
EP3351633B1 (en) 2015-09-15 2020-06-24 Nippon Shinyaku Co., Ltd. Antisense nucleic acid
CN108738310A (zh) * 2015-09-30 2018-11-02 萨勒普塔医疗公司 用于治疗肌营养不良的方法
WO2017062862A2 (en) 2015-10-09 2017-04-13 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
BR112018007066A2 (pt) 2015-10-09 2018-10-23 Sarepta Therapeutics Inc composições e métodos para tratamento da distrofia muscular de duchene e distúrbios relacionados
EP4089175A1 (en) 2015-10-13 2022-11-16 Duke University Genome engineering with type i crispr systems in eukaryotic cells
GB2545898B (en) * 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
BR112018074346B1 (pt) 2016-05-24 2023-01-03 Sarepta Therapeutics, Inc. Composto oligomérico e processo para preparar um composto oligomérico
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
EP3478697A1 (en) 2016-06-30 2019-05-08 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
EP3487523B1 (en) * 2016-07-19 2023-09-06 Duke University Therapeutic applications of cpf1-based genome editing
MX2019006157A (es) * 2016-11-28 2019-11-21 Univ Texas Prevención de la distrofia muscular mediante la edición de genes mediada por crispr/cpf1.
HUE060065T2 (hu) * 2016-12-19 2023-01-28 Sarepta Therapeutics Inc Exonátugró oligomerkonjugátumok izomdisztrófiára
DK3554553T3 (da) 2016-12-19 2022-09-19 Sarepta Therapeutics Inc Exon-overspringnings-oligomerkonjugat til muskeldystrofi
RS63621B1 (sr) 2016-12-19 2022-10-31 Sarepta Therapeutics Inc Oligomerni konjugati za preskakanje egzona za mišićnu distrofiju
CA3049424A1 (en) 2017-01-06 2018-07-12 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
KR20190134673A (ko) * 2017-03-30 2019-12-04 고쿠리츠 다이가쿠 호진 교토 다이가쿠 게놈 편집에 의한 엑손 스키핑 유도 방법
US11622960B2 (en) 2017-06-19 2023-04-11 University Of Maryland, Baltimore Microtubule polymerization inhibitor prodrugs and methods of using the same
AU2018302098A1 (en) 2017-07-18 2020-02-20 Csl Behring Gene Therapy, Inc. Compositions and methods for treating beta-hemoglobinopathies
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
CA3075425A1 (en) * 2017-09-22 2019-03-28 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and methods of inducing exon skipping
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EP3694543A1 (en) 2017-10-13 2020-08-19 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
EP3697910A4 (en) * 2017-10-18 2021-07-14 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERIC COMPOUNDS
KR102623786B1 (ko) 2017-12-06 2024-01-11 어비디티 바이오사이언시스 인크. 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
WO2019152609A1 (en) * 2018-01-31 2019-08-08 The Board Of Regents Of The University Of Texas System Compositions and methods for correcting dystrophin mutations in human cardiomyocytes
BR112020021179A2 (pt) * 2018-04-16 2021-03-02 The Trustees Of The University Of Pennsylvania composições e métodos para tratar distrofia muscular de duchenne
WO2019209764A2 (en) * 2018-04-26 2019-10-31 Sarepta Therapeutics, Inc. Exon skipping oligomers and oligomer conjugates for muscular dystrophy
US10758629B2 (en) * 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
JP2021526796A (ja) * 2018-06-13 2021-10-11 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマー
BR112020026542A2 (pt) 2018-06-26 2021-04-06 Nippon Shinyaku Co., Ltd. Composição que compreende oligonucleotídeo antissenso e uso da mesma para tratamento de distrofia muscular de duchenne
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP3874044A1 (en) * 2018-11-02 2021-09-08 BioMarin Technologies B.V. Bispecific antisense oligonucleotides for dystrophin exon skipping
WO2020123574A1 (en) * 2018-12-13 2020-06-18 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
KR20210118402A (ko) 2018-12-23 2021-09-30 씨에스엘 베링 엘엘씨 위스콧-알드리치(Wiskott-Aldrich) 증후군에 대한 조혈 줄기 세포-유전자 치료요법
BR112021012318A2 (pt) 2018-12-23 2022-01-18 Csl Behring Llc Células t doadoras com interruptor de eliminação
EP3954395A4 (en) * 2019-04-08 2023-06-28 National University Corporation Tokyo Medical and Dental University Pharmaceutical composition for muscle disease treatment
WO2020219820A1 (en) * 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
BR112021023594A2 (pt) 2019-05-28 2022-02-08 Selecta Biosciences Inc Métodos e composições para resposta imune de vetor de transferência antiviral atenuada
WO2021003573A1 (en) * 2019-07-09 2021-01-14 The Governors Of The University Of Alberta Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene
EP4007633A4 (en) * 2019-08-02 2024-05-08 Research Institute at Nationwide Children's Hospital NUCLEIC ACIDS TARGETING EXON 44 AND RECOMBINANT ADENO-ASSOCIATED VIRUS COMPRISING SAID NUCLEIC ACIDS FOR THE TREATMENT OF DYSTROPHIN-BASED MYOPATHIES
MX2022007491A (es) 2019-12-19 2022-08-15 Nippon Shinyaku Co Ltd Acido nucleico antisentido que permite la omision de exones.
WO2021132591A1 (ja) 2019-12-26 2021-07-01 日本新薬株式会社 エクソン５０のスキッピングを誘導するアンチセンス核酸
BR112022017066A2 (pt) * 2020-02-28 2022-11-16 Nippon Shinyaku Co Ltd Ácido nucleico antissentido indutor de salto do éxon 51
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
WO2021263070A1 (en) 2020-06-26 2021-12-30 Csl Behring Llc Donor t-cells with kill switch
EP3978608A1 (en) * 2020-10-05 2022-04-06 SQY Therapeutics Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
WO2022171972A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
MX2023011612A (es) 2021-03-31 2023-12-15 Entrada Therapeutics Inc Peptidos de penetracion celular ciclicos.
IL308353A (en) 2021-05-10 2024-01-01 Entrada Therapeutics Inc Compositions and methods for modulating tissue distribution of intracellular therapies
WO2022239863A1 (ja) 2021-05-13 2022-11-17 国立大学法人千葉大学 アンチセンスオリゴマー
CN117500925A (zh) * 2021-05-28 2024-02-02 住友制药株式会社 反义核酸
JP7522079B2 (ja) 2021-06-16 2024-07-24 株式会社神戸製鋼所 積層計画作成方法
KR20240024176A (ko) 2021-06-23 2024-02-23 니뽄 신야쿠 가부시키가이샤 안티센스 올리고머의 조합
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
AU2022345098A1 (en) 2021-09-16 2024-04-04 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
AU2022424485A1 (en) 2021-12-27 2024-07-11 Nippon Shinyaku Co., Ltd. Method for producing oligonucleic acid compound
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
AU2023254846A1 (en) 2022-04-15 2024-10-10 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
WO2023205451A1 (en) 2022-04-22 2023-10-26 Entrada Therapeutics, Inc. Cyclic peptides for delivering therapeutics
WO2023250511A2 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
WO2024112809A2 (en) * 2022-11-21 2024-05-30 Pepgen Inc. Cell-penetrating peptides, conjugates thereof, and methods of their use

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
DE3100514A1 (de) 1981-01-10 1982-08-05 Robert Bosch Gmbh, 7000 Stuttgart Vorrichtung zur steuerung eines durchflussquerschnittes in einer steuerleitung
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US20020123476A1 (en) 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US5869252A (en) 1992-03-31 1999-02-09 Abbott Laboratories Method of multiplex ligase chain reaction
DE69329641T2 (de) 1992-03-31 2001-06-21 Abbott Laboratories, Abbott Park Verfahren zur mehrfachen ligase-kettenreaktion
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
AU4769893A (en) 1992-07-17 1994-02-14 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
ATE368107T1 (de) 1993-05-11 2007-08-15 Univ North Carolina Antisense oligonukleotide die anomales splicing verhindern und deren verwendung
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9510718D0 (en) 1995-05-26 1995-07-19 Sod Conseils Rech Applic Antisense oligonucleotides
DK0882061T3 (da) 1996-02-14 2004-09-27 Isis Pharmaceuticals Inc Sukkermodificerede gapped oligonukleotider
WO1997034638A1 (en) 1996-03-20 1997-09-25 The Regents Of The University Of California Antisense approach to gene inhibition
US6153436A (en) 1997-01-10 2000-11-28 The Board Of Trustees Of The University Of Arkansas Method of gene delivery using wildtype adeno associated viral (AAV) vectors with insertions
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
US20030114401A1 (en) 2001-12-06 2003-06-19 Isis Pharmaceuticals Inc. Antisense modulation of Ship-1 expression
GB9819999D0 (en) 1998-09-14 1998-11-04 Univ London Treatment of cancer
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
CA2350531A1 (en) 1998-11-13 2000-05-25 Smriti Iyengar Method for treating pain
WO2000045167A2 (en) 1999-01-29 2000-08-03 Avi Biopharma, Inc. Non-invasive method for detecting target rna
US20020049173A1 (en) 1999-03-26 2002-04-25 Bennett C. Frank Alteration of cellular behavior by antisense modulation of mRNA processing
JP2000325085A (ja) 1999-05-21 2000-11-28 Masafumi Matsuo デュシェンヌ型筋ジストロフィー治療剤
CA2374499A1 (en) * 1999-05-24 2000-11-30 Avi Biopharma, Inc. Antisense to c-myc for treatment of polycystic kidney disease
WO2000078341A1 (en) 1999-06-21 2000-12-28 Murdoch Childrens Research Institute A method for the prophylaxis and/or treatment of medical disorders
US7163695B2 (en) 1999-12-29 2007-01-16 Mixson A James Histidine copolymer and methods for using same
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
KR20020079768A (ko) 2000-01-04 2002-10-19 에이브이아이 바이오파마 인코포레이티드 안티센스 항박테리아 세포분열 조성물 및 방법
JP2004509604A (ja) 2000-03-28 2004-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド ｍＲＮＡプロセッシングのアンチセンスモジュレーションによる、細胞行動の改変
US6653467B1 (en) 2000-04-26 2003-11-25 Jcr Pharmaceutical Co., Ltd. Medicament for treatment of Duchenne muscular dystrophy
ATE437944T1 (de) 2000-04-28 2009-08-15 Asklepios Biopharmaceutical In Für das dystrophin-minigen kodierende dna- sequenzen und verfahren zu deren verwendung
JP2003531915A (ja) 2000-05-01 2003-10-28 ハイブリドン・インコーポレイテッド ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
WO2001083740A2 (en) 2000-05-04 2001-11-08 Avi Biopharma, Inc. Splice-region antisense composition and method
JP4836366B2 (ja) 2000-08-25 2011-12-14 雅文 松尾 デュシェンヌ型筋ジストロフィー治療剤
US6727355B2 (en) 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
US7264925B2 (en) 2000-08-30 2007-09-04 Avi Biopharma, Inc. Method for analysis of oligonucleotide analogs
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6559279B1 (en) 2000-09-08 2003-05-06 Isis Pharmaceuticals, Inc. Process for preparing peptide derivatized oligomeric compounds
JP2004509619A (ja) 2000-09-20 2004-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド Ｆｌｉｐ−ｃ発現のアンチセンスモジュレーション
EP1191097A1 (en) 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US6689615B1 (en) 2000-10-04 2004-02-10 James Murto Methods and devices for processing blood samples
JP3781687B2 (ja) 2001-02-23 2006-05-31 松下電器産業株式会社 遺伝子診断装置及び遺伝子診断方法
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
US7655785B1 (en) 2002-11-14 2010-02-02 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7314750B2 (en) 2002-11-20 2008-01-01 Affymetrix, Inc. Addressable oligonucleotide array of the rat genome
US7250289B2 (en) 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
JP4777777B2 (ja) 2002-11-25 2011-09-21 雅文 松尾 ｍＲＮＡ前駆体のスプライシングを修飾するＥＮＡ核酸医薬
WO2004083432A1 (en) 2003-03-21 2004-09-30 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
DE602004028930D1 (de) 2003-04-29 2010-10-14 Avi Biopharma Inc Zusammensetzungen zur verbesserung der antisense-wirksamkeit und des transports von nukleinsäureanalog in zellen
EP1495769B1 (en) 2003-07-11 2008-02-27 LBR Medbiotech B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
CA2533218C (en) 2003-08-05 2014-11-18 Avi Biopharma, Inc. Oligonucleotide analog and method for treating flavivirus infections
US20050048495A1 (en) 2003-08-29 2005-03-03 Baker Brenda F. Isoform-specific targeting of splice variants
US20050153935A1 (en) 2003-09-12 2005-07-14 Iversen Patrick L. Compound and method for treating androgen-independent prostate cancer
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
EP2500430B1 (en) 2004-06-28 2017-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US20060148740A1 (en) 2005-01-05 2006-07-06 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
US20120122801A1 (en) 2005-01-05 2012-05-17 Prosensa B.V. Mannose-6-phosphate receptor mediated gene transfer into muscle cells
EP1855694B1 (en) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense composition for treating muscle atrophy
KR20080031164A (ko) 2005-04-22 2008-04-08 아카데미슈 지켄후이스 라이덴 ＳＲ 단백질의 결합의 방해에 의해 그리고 이차 ＲＮＡ구조의 방해에 의한 ｐｒｅ－ｍＲＮＡ에서 엑손 인식의조절
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
EP1937312B1 (en) 2005-08-30 2016-06-29 Ionis Pharmaceuticals, Inc. Chimeric oligomeric compounds for modulation of splicing
WO2007030691A2 (en) 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
JP2009515523A (ja) 2005-11-10 2009-04-16 サンタリス ファーマ アー／エス Ｔｎｆスーパーファミリー受容体に対するスプライス切替オリゴマーならびに疾病治療における該オリゴマーの使用
US20090011004A1 (en) * 2005-12-30 2009-01-08 Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine Improved carriers for delivery of nucleic acid agents to cells and tissues
US8785407B2 (en) 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
SI2024499T1 (en) 2006-05-10 2018-04-30 Sarepta Therapeutics, Inc. Analogues of the oligonucleotide, with cationic links between subunits
US20070265215A1 (en) 2006-05-11 2007-11-15 Iversen Patrick L Antisense restenosis composition and method
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
ES2694726T3 (es) 2007-06-29 2018-12-26 Sarepta Therapeutics, Inc. Conjugados peptídicos específicos de tejido y métodos
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009054725A2 (en) 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
WO2009101399A1 (en) 2008-02-12 2009-08-20 Isis Innovation Limited Treatment of muscular dystrophy using peptide nucleic acid ( pna)
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
CN102203253B (zh) 2008-10-24 2016-04-06 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
ES2562658T3 (es) 2008-10-27 2016-03-07 Biomarin Technologies B.V. Procedimientos y medios para el salto eficiente del exón 45 en el pre-ARNm de la distrofia muscular de Duchenne
EP2376633A1 (en) 2008-12-17 2011-10-19 AVI BioPharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
PT2417257E (pt) 2009-04-10 2016-06-03 Universität Bern Oligonucleótidos triciclo-dna anti-sentido, composições, e métodos para o tratamento de doença
ES2593836T3 (es) 2009-04-24 2016-12-13 Biomarin Technologies B.V. Oligonucleótido que comprende una inosina para tratar la DMD
US9034838B2 (en) 2009-05-25 2015-05-19 Universita Degli Studi Di Roma “La Sapienza” miR-31 in duchenne muscular dystrophy therapy
EP2258863A1 (en) 2009-05-25 2010-12-08 Universita'Degli Studi di Roma "La Sapienza" miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
ITTO20090487A1 (it) 2009-06-26 2010-12-27 Univ Ferrara Oligonucleotidi antisenso atti ad indurre lo skipping esonico e loro impiego come medicamento per il trattamento della distrofia muscolare di duchenne (dmd)
WO2011024077A2 (en) 2009-08-31 2011-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Exon skipping therapy for functional amelioration of semi functional dystrophin in becker and duchenne muscular dystrophy
IT1397011B1 (it) 2009-10-14 2012-12-20 Univ Ferrara Nanoparticella del tipo core-shell idonea per la veicolazione di oligonucleotidi terapeutici in tessuti bersaglio e suo impiego per la preparazione di un medicamento per il trattamento della distrofia muscolare di duchenne.
WO2011057350A1 (en) 2009-11-12 2011-05-19 The University Of Western Australia Antisense molecules and methods for treating pathologies
TWI495473B (zh) 2009-11-13 2015-08-11 Sarepta Therapeutics Inc 反義抗病毒化合物及治療流感病毒感染的方法
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
BR112012031363A2 (pt) 2010-05-28 2021-10-26 Sarepta Therapeutcs, Inc Análogos de oligonucleotídeo tendo ligações intersubunidades modificadas e/ou grupos terminais.
WO2012001941A1 (ja) 2010-06-28 2012-01-05 Hagiwara Masatoshi 遺伝性疾患の予防・改善剤
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
RS55610B1 (sr) 2010-09-30 2017-06-30 Nippon Shinyaku Co Ltd Derivat morfolino nukleinske kiseline
JP2014507143A (ja) 2011-02-08 2014-03-27 ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング／ビジネス／アズ キャロライナズ ヘルスケア システム アンチセンスオリゴヌクレオチド
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
WO2012150960A1 (en) 2011-05-05 2012-11-08 Avi Biopharma, Inc. Peptide oligonucleotide conjugates
US20140080896A1 (en) 2011-08-30 2014-03-20 The Regents Of The University Of California Identification of small molecules that facilitate therapeutic exon skipping
WO2013033407A2 (en) 2011-08-30 2013-03-07 The Regents Of The University Of California Identification of small molecules that enhance therapeutic exon skipping
EP2581448B1 (en) 2011-10-13 2015-01-28 Association Institut de Myologie Tricyclo-phosphorothioate DNA
IN2014DN06220A (pt) 2011-12-28 2015-10-23 Nippon Shinyaku Co Ltd
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
RU2674600C2 (ru) 2012-07-03 2018-12-11 Просенса Текнолоджиз Б.В. Олигонуклеотид для лечения пациентов с мышечной дистрофией
WO2014015322A1 (en) 2012-07-20 2014-01-23 Dockwing, LLC Massager comprising balls and an oversleeve shrink- fitted over the balls and method of making the same
KR20200143739A (ko) 2012-12-20 2020-12-24 사렙타 쎄러퓨틱스 인코퍼레이티드 근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물
US20160040162A1 (en) 2013-03-14 2016-02-11 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
IL293975A (en) 2013-03-14 2022-08-01 Sarepta Therapeutics Inc Preparations that skip axon for the treatment of muscular dystrophy
NZ732507A (en) 2013-03-15 2018-08-31 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy

Also Published As

Publication number Publication date
US9234198B1 (en) 2016-01-12
US8871918B2 (en) 2014-10-28
US8865883B2 (en) 2014-10-21
JP2021100439A (ja) 2021-07-08
TW201831687A (zh) 2018-09-01
JP2019178163A (ja) 2019-10-17
JP2021088595A (ja) 2021-06-10
IL278833A (en) 2021-01-31
EP3133160A1 (en) 2017-02-22
AU2009308167A1 (en) 2010-04-29
US20160002633A1 (en) 2016-01-07
TWI639700B (zh) 2018-11-01
US20190127738A1 (en) 2019-05-02
TW202043473A (zh) 2020-12-01
TW201018471A (en) 2010-05-16
HRP20190387T1 (hr) 2019-05-31
JP2016195616A (ja) 2016-11-24
EP2762567A1 (en) 2014-08-06
IL313162A (en) 2024-07-01
JP2017086087A (ja) 2017-05-25
BR122020021379B1 (pt) 2021-05-11
IL304042A (en) 2023-08-01
IL212386A (en) 2016-10-31
KR20180118828A (ko) 2018-10-31
US20100130591A1 (en) 2010-05-27
IL269664A (en) 2019-11-28
TWI488965B (zh) 2015-06-21
EP3428278A1 (en) 2019-01-16
US20150376618A1 (en) 2015-12-31
US9447416B2 (en) 2016-09-20
US20160002634A1 (en) 2016-01-07
US20170292125A1 (en) 2017-10-12
US20150376617A1 (en) 2015-12-31
EP2350281A1 (en) 2011-08-03
HK1200868A1 (en) 2015-08-14
ES2714787T3 (es) 2019-05-30
KR20110082576A (ko) 2011-07-19
US20130190390A1 (en) 2013-07-25
US20210180060A1 (en) 2021-06-17
TR201902952T4 (tr) 2019-03-21
US9434948B2 (en) 2016-09-06
CA3066050A1 (en) 2010-04-29
JP2023055956A (ja) 2023-04-18
KR20190079702A (ko) 2019-07-05
CN112574988A (zh) 2021-03-30
EP3404100A1 (en) 2018-11-21
US20190284556A1 (en) 2019-09-19
EP2350281B1 (en) 2014-05-14
AU2009308167B2 (en) 2016-03-31
US9447417B2 (en) 2016-09-20
CN102203253B (zh) 2016-04-06
EP3875587A1 (en) 2021-09-08
JP2018113989A (ja) 2018-07-26
JP2012506703A (ja) 2012-03-22
CA2740328A1 (en) 2010-04-29
LT3133160T (lt) 2019-04-10
US20180066259A1 (en) 2018-03-08
JP5864257B2 (ja) 2016-02-17
PL3133160T3 (pl) 2019-06-28
JP2015017131A (ja) 2015-01-29
HUE042979T2 (hu) 2019-07-29
EP2762567B1 (en) 2016-07-13
TW201534719A (zh) 2015-09-16
JP6406782B2 (ja) 2018-10-17
CN105779453A (zh) 2016-07-20
EP3133160B1 (en) 2018-12-12
US20160002637A1 (en) 2016-01-07
ES2955539T3 (es) 2023-12-04
KR20230025924A (ko) 2023-02-23
DK3133160T3 (en) 2019-04-01
IL246697A0 (en) 2016-08-31
SI3133160T1 (sl) 2019-05-31
CY1122369T1 (el) 2021-01-27
TW202309285A (zh) 2023-03-01
BR122020021368B1 (pt) 2021-06-08
WO2010048586A1 (en) 2010-04-29
JP6429285B2 (ja) 2018-11-28
CN102203253A (zh) 2011-09-28
IL246697B (en) 2019-12-31
US20150152415A1 (en) 2015-06-04
TW201712120A (en) 2017-04-01
PT3133160T (pt) 2019-03-18
TWI689587B (zh) 2020-04-01
KR20180011364A (ko) 2018-01-31
EP3875587B1 (en) 2023-07-12
US20140094500A1 (en) 2014-04-03
TWI563086B (en) 2016-12-21
EP4174178A1 (en) 2023-05-03
BRPI0920276B1 (pt) 2021-06-08
JP2023073441A (ja) 2023-05-25
US9453225B2 (en) 2016-09-27
IL212386A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
BRPI0920276A2 (pt) várias composições para exclusão de exon dmd
LTPA2019009I1 (lt) C7-fluoru pakeisti tetraciklino junginiai
BRPI0821731A2 (pt) Composições cosméticas para conceder flimes superhidrofóbicos
SMT201500263B (it) Composizioni solide
DK2634232T3 (da) Sammensætninger
BRPI0918971A2 (pt) tienopirimidinas para composições farmacêuticas
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
BRPI0918838A2 (pt) processos para preparação de composições de polipeptídeos purificados
DK2214679T3 (da) Kortikosteroidsammensætninger
DOP2011000396A (es) Composiciones novedosas
SMT201600307B (it) Composizione liposomiale
UY33161A (es) Composiciones plaguicidas
BRPI0810634A2 (pt) Composições fungicidas
BR112012005237A2 (pt) utilização de composições ternárias
BRPI1013588A2 (pt) composição
BRPI1015474A2 (pt) composição
BR112013028128A2 (pt) composição de polímero para dispositivos elétricos
BR112012004080A2 (pt) composições farmacêuticas para tratar ibd
BRPI1009901A2 (pt) composição para inibição da formação de incrustação de cálcio
BRPI0919037A2 (pt) composições lubrificantes
BRPI1010690A2 (pt) composições
BR112013028282A2 (pt) composição de polímero para dispositivos elétricos
DK2431450T3 (da) Bionedbrydelig smøremiddelsammensætning
BRPI1005318A2 (pt) composição
BR112012000955A2 (pt) composição lubrificante

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SAREPTA THERAPEUTICS , INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: SAREPTA THERAPEUTICS , INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF